MaxCyte stock analysis
Want to see MXCT full AI Analyst Report?
MaxCyte (MXCT) Stock Price & Analysis
MXCT Stock Chart & Stats
- Day’s Range
- $1.15 - $1.28
- 52-Week Range
- $0.64 - $1.81
- Previous Close
- $1.19
- Volume
- N/A
- Average Volume (3M)
- 1.66M
- Market Cap
- $121.84M
- Enterprise Value
- $31.57M
- Total Cash (Recent Filing)
- $101.28M
- Total Debt (Recent Filing)
- $16.89M
- Price to Earnings (P/E)
- ―
- Beta
- 1.13
- Next Earnings
- Mar 16, 2027 (Est.)
- EPS Estimate
- -0.07
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Recent revenue acceleration and raised guidance indicate improving customer demand across core products and strategic programs. If sustained, this growth can expand the installed base, increase consumables utilization, and improve operating leverage as revenue scales over the next several quarters.
Strong Gross Margins
Persistently high gross margins suggest the platform has attractive underlying unit economics and proprietary technology value. Maintaining margins in the high 70s would give MaxCyte meaningful capacity to fund product development, absorb commercial expansion costs, and improve profitability as volume grows.
Expanded Commercial Platform
Akron would broaden MaxCyte beyond its existing electroporation focus into reagents and ancillary materials used across cell and gene therapy programs. The larger addressable market, higher recurring mix, and stated cross-selling opportunity could make revenue more diversified and durable if integration succeeds.
Bears Say
Persistent Unprofitability
MaxCyte has not yet demonstrated sustained operating leverage, with its current cost base still far above revenue and profitability remaining deeply negative. Continued losses can consume capital, limit strategic flexibility, and make future growth dependent on successfully scaling revenue or reducing expenses.
Ongoing Cash Burn
Persistent negative operating and free cash flow means the business is not currently self-funding its operations or investments. Even with expected improvement, ongoing cash consumption raises funding risk and leaves less financial capacity to withstand delays in customer programs, milestones, or commercialization.
Acquisition Financing Risk
The Akron transaction materially increases near-term cash commitments and introduces debt service and deferred-payment obligations while MaxCyte remains loss-making. Management expects only $40 million to $45 million of cash at closing, reducing liquidity available for execution and unexpected integration costs.
MaxCyte News
MXCT FAQ
What was MaxCyte’s price range in the past 12 months?
What is MaxCyte’s market cap?
When is MaxCyte’s upcoming earnings report date?
How were MaxCyte’s earnings last quarter?
Is MaxCyte overvalued?
Does MaxCyte pay dividends?
What is MaxCyte’s EPS estimate?
How many shares outstanding does MaxCyte have?
What happened to MaxCyte’s price movement after its last earnings report?
Which hedge fund is a major shareholder of MaxCyte?
What is the TipRanks Smart Score and how is it calculated?
MaxCyte Stock Smart Score
Company Description
MaxCyte
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Maher Masoud
- Employees
- 91
- Website
- www.maxcyte.com
- Address
- 9713 Key West Avenue, Rockville, MD, 20850, US
MaxCyte (MXCT) Earnings & Revenues
MXCT Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, driven by 49% third-quarter revenue growth, raised 2026 guidance, improving core and PA revenue trends, growing CASGEVY royalties, a broad clinical and commercial pipeline, and the proposed Akron acquisition's expected contribution of scale, recurring revenue, EBITDA, and cash flow. The company also reported materially lower operating expenses and a reduced net loss. The principal negative items were the substantial cash and financing requirements for the acquisition, expected acquisition-related reductions to actual year-end cash, ongoing standalone cash burn, fourth-quarter CASGEVY seasonality, and quarterly lumpiness in assay services. Highlights significantly outweighed lowlights.
View all MXCT earnings summariesMXCT Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 6 | 11 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 3 | 0 | 9 |













